REPLICA: Real Patient Life Treatment With Cabozantinib in Monotherapy or in Combination With Nivolumab in Patients With Advanced or Metastatic RCC: a Descriptive and Prospective Non Interventional Study.
Condition: Advanced or Metastatic Renal Cell Carcinoma
Study Type: Observational
Clinical Trials Identifier NCT 8-digits: NCT04106349
Sponsor: Ipsen
Phase:
Eligibility:
- Age: minimum 18 Years maximum N/A
- Gender: All
Inclusion Criteria:
- Males or females aged 18 years and older
- Patients scheduled to receive Cabometyx® in monotherapy or in combination with nivolumabfor advanced or metastatic renal cell carcinoma
- Decision to treat patients with Cabometyx® in monotherapy or in combination with nivolumab has to be taken prior to and independent from participation in the clinical study
- Provision of written informed consent
Exclusion Criteria:
- Participation in another interventional clinical study at the same time
- Previous participation in this clinical study
View trial on ClinicalTrials.gov